Table 1.
Baseline characteristics of study patients.
| Parameter | Biliary Disease (n = 34) |
|---|---|
| Age (range), years | 71 (47–85) |
| Sex, male/female | 19/15 |
| Location of stricture (perihilar/distal) | 12/22 |
| Malignant | 6/12 |
| Benign | 6/10 |
| Length of stricture, mm | 16.2 (1.2–46.0) |
| Acute cholangitis (presence/absence) | 4/30 |
| Total bilirubin, mg/dL | 1.2 (0.3–25.4) |
| Tumor marker | |
| CEA, ng/mL | |
| Malignant | 2.4 (1.2–8.3) |
| Benign | 2.2(1.4–4.2) |
| CA19-9, U/mL | |
| Malignant | 57.9 (0.8–11985) * |
| Benign | 7.7 (1.6–71.6) |
| Malignant | 18 |
| cholangiocarcinoma | 18 |
| Benign | 16 |
| Benign biliary stricture | 11 |
| IgG4-associated sclerosing cholangitis | 1 |
| Primary sclerosing cholangitis | 1 |
| Intraductal papillary neoplasm of bile duct | 1 |
| Bile duct adenoma | 1 |
| Peribiliary cyst | 1 |
Values are presented as number or median (range). Abbreviations: CEA, carcinoembryonic antigen; CA19-9, carbohydrate antigen 19-9; IgG4, immunoglobulin G subclass 4. * p < 0.001 compared with benign biliary disease.